MARKET

ONCY

ONCY

Oncolytics Biotech Inc
NASDAQ
0.6833
+0.0041
+0.60%
After Hours: 0.6700 -0.0133 -1.95% 19:30 09/25 EDT
OPEN
0.6900
PREV CLOSE
0.6792
HIGH
0.6940
LOW
0.6670
VOLUME
826.24K
TURNOVER
--
52 WEEK HIGH
1.510
52 WEEK LOW
0.6419
MARKET CAP
87.13M
P/E (TTM)
-2.1254
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Spyre Therapeutics (SYRE)
TipRanks · 5h ago
Oncolytics Biotech (ONCY) Receives a Rating Update from a Top Analyst
TipRanks · 6d ago
Weekly Report: what happened at ONCY last week (0914-0918)?
Weekly Report · 6d ago
Weekly Report: what happened at ONCY last week (0907-0911)?
Weekly Report · 09/14 10:19
Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials
NASDAQ · 09/11 16:06
Oncolytics Biotech Reports Positive Pelareorep Preclinical Results
TipRanks · 09/10 12:48
Oncolytics Biotech Reports Encouraging Pelareorep Data In Colorectal Cancer
NASDAQ · 09/10 12:26
Oncolytics reports pelareorep preclinical results
TipRanks · 09/10 12:20
More
About ONCY
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Webull offers Oncolytics Biotech Inc stock information, including NASDAQ: ONCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONCY stock methods without spending real money on the virtual paper trading platform.